市场整体情绪与表现 - CNN恐惧与贪婪指数显示市场恐惧水平进一步缓解，读数从286升至331，但仍处于“恐惧”区间 [1][5] - 美国主要股指在周五均创下历史新高，道琼斯指数上涨约473点至47,20712点，标普500指数上涨079%至6,79169点，纳斯达克综合指数上涨115%至23,20487点 [4] - 市场上涨主要受低于预期的通胀数据推动，增强了市场对美联储将在10月30日政策会议上降息25个基点的预期 [1] 通胀数据 - 2025年9月年度整体通胀率为3%，略高于8月的29%，但低于31%的预期 [2] - 剔除食品和能源的核心通胀率从31%降至3%，低于预期 [2] 个股表现 - 福特汽车公司因第三季度盈利超预期，股价飙升12%，创下自2022年以来最佳单日表现 [2] - Inhibrx Biosciences公司因宣布其癌症药物ozekibart的试验结果令人鼓舞，股价大涨102% [3] 板块表现 - 标普500指数中多数板块收涨，信息技术、通信服务和公用事业板块涨幅最大 [3] - 能源和材料板块逆市收跌 [3] 未来关注点 - 投资者正等待Keurig Dr Pepper公司、Nucor公司以及Waste Management公司即将公布的财报 [4]

公司股价表现 - Wellgistics Health Inc (NASDAQ:WGRX) 股价飙升至108美元，涨幅达168.16% [1][5] - MaxsMaking Inc (NASDAQ:MAMK) 股价上涨至743美元，涨幅为148.70% [1][5] - Inhibrx Biosciences Inc (NASDAQ:INBX) 股价升至5513美元，涨幅为94.43% [2][5] - Genenta Science SpA (NASDAQ:GNTA) 股价上涨至622美元，涨幅达92.72% [3] 公司业务与驱动因素 - Wellgistics Health 为药品批发分销商，专注于仿制药和品牌药分销以及第三方物流服务，其股价上涨与宣布同Datavault AI Inc (NASDAQ:DVLT) 就整合区块链智能合约至处方药追踪系统的无约束力意向书有关 [1] - MaxsMaking 为中国定制消费纺织品制造商，采用专有系统实现高效生产，其股价上涨与成功完成首次公开募股筹集650万美元并于2025年7月7日在纳斯达克资本市场开始交易相关 [1][5] - Inhibrx Biosciences 为临床阶段生物制药公司，专注于开发针对危及生命疾病的生物疗法，其股价上涨与其中期试验显示实验性药物有效减缓一种罕见侵袭性骨癌的进展相关 [2][5] - Genenta Science 致力于开发造血干细胞基因疗法，其股价上涨与同ANEMOCYTE建立战略合作伙伴关系以推进现成慢病毒载体质粒DNA生产相关 [3] 交易量与行业背景 - Wellgistics Health 交易量超过6.14亿股，远高于其平均水平 [1] - MaxsMaking 交易量超过140万股 [1] - Inhibrx Biosciences 交易量超过500万股 [2] - Genenta Science 交易量超过2000万股 [3] - 股价变动反映了从医疗保健、生物技术到消费品和科技等多个行业的动态，临床试验结果、战略合作、创新产品供应和市场趋势是主要驱动因素 [4]

作者及服务介绍 - 文章作者Terry Chrisomalis运营名为Biotech Analysis Central的医药服务，该服务提供对多家医药公司的深度分析 [1] - Biotech Analysis Central服务在Seeking Alpha平台的订阅价格为每月49美元，年度计划可享受3350%的折扣，价格为每年399美元 [1] - 作者所属的投资小组Biotech Analysis Central拥有一个包含600多篇生物技术投资文章的资料库，以及一个包含10多只中小盘股票的投资组合模型 [2] 公司历史关联 - 作者此前曾撰写关于Inhibrx Biosciences Inc的文章，题为"Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi" [2]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

盘前交易概况 - 美国东部时间周五早上7点45分 盘前交易出现显著活动 多只股票出现早期价格变动 预示着开盘前的潜在机会 [1] - 对于活跃交易者而言 盘前交易有助于提前发现潜在突破、反转或剧烈价格波动 这些早期动向通常预示常规交易时段的动量走向 [1] 盘前涨幅居前股票 - Qualigen Therapeutics Inc (QLGN) 股价上涨69%至6.00美元 [3] - Inhibrx Biosciences Inc (INBX) 股价上涨62%至46.04美元 [3] - MidWestOne Financial Group Inc (MOFG) 股价上涨33%至37.87美元 [3] - Neuphoria Therapeutics Inc (NEUP) 股价上涨31%至5.32美元 [3] - Nextracker Inc (NXT) 股价上涨13%至102.44美元 [3] - Avalon Holdings Corporation (AWX) 股价上涨11%至2.98美元 [3] - Beyond Meat Inc (BYND) 股价上涨9%至3.12美元 [3] - SLM Corporation (SLM) 股价上涨8%至29.00美元 [3] - Reborn Coffee Inc (REBN) 股价上涨7%至2.40美元 [3] - Oriental Culture Holding LTD (OCG) 股价上涨5%至3.55美元 [3] 盘前跌幅居前股票 - Picard Medical Inc (PMI) 股价下跌70%至3.89美元 [4] - Fusemachines Inc Common stock (FUSE) 股价下跌17%至3.29美元 [4] - American Rebel Holdings Inc (AREB) 股价下跌16%至3.14美元 [4] - Armata Pharmaceuticals Inc (ARMP) 股价下跌13%至6.16美元 [4] - Coya Therapeutics Inc (COYA) 股价下跌13%至6.01美元 [4] - Deckers Outdoor Corporation (DECK) 股价下跌12%至90.00美元 [4] - Safe & Green Holdings Corp (SGBX) 股价下跌12%至2.58美元 [4] - Beasley Broadcast Group Inc (BBGI) 股价下跌8%至5.55美元 [4] - Booz Allen Hamilton Holding Corporation (BAH) 股价下跌7%至92.73美元 [4] - Brera Holdings PLC (SLMT) 股价下跌6%至10.67美元 [4]

Inhibrx Biosciences Inc. (NASDAQ:INBX) shares rose 75.95% in after-hours trading on Thursday, closing at $49.90.Check out the current price of INBX stock here. According to Benzinga Pro data, the stock closed regular trading at $28.36, down 10.03%.ChonDRAgon Study Results AnnouncedOn Thursday, the California-based clinical-stage biopharmaceutical company announced positive topline results from the registrational ChonDRAgon study, a Phase 2 trial evaluating ozekibart (INBRX-109) as a single agent versus plac ...

Biotech stocks led the after-hours charge on Thursday, with Inhibrx Biosciences (INBX) skyrocketing over 81% on positive Phase 2 trial results in chondrosarcoma. Femasys (FEMY), Cingulate (CING), and Community Health Systems (CYH) also posted notable gains, driven by clinical milestones and upbeat earnings. Here's a look at the top post-market movers.Shares of Inhibrx Biosciences Inc. (INBX) surged over 81% at $51.52 in after-hours trading, propelled by positive topline results from its registrational Chon ...

Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer in a mid-stage trial, sending its shares surging over 70% in extended tradin... ...

Accessibility StatementSkip Navigation SAN DIEGO, Oct. 23, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced positive topline results from the registrational ChonDRAgon study (n= 206) investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma. Â The Company also pr ...

Biotech stocks surged in after-hours trading on Wednesday, October 22, led by Ventyx Biosciences, which soared over 88% on positive Phase 2 data. A mix of earnings updates, clinical news, and investor interest lifted several names across the sector, including Medpace, Inhibrx, and Acumen Pharmaceuticals. Here's a look at the biggest movers.Shares of Ventyx Biosciences Inc. (VTYX) are up over 88% after hours after the company reported the positive results from its Phase 2 study of oral, once-daily VTX3232 i ...